Barclays PLC Sells 107,437 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Barclays PLC lessened its position in The Cooper Companies, Inc. (NASDAQ:COO) by 23.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 355,510 shares of the medical device company’s stock after selling 107,437 shares during the period. Barclays PLC’s holdings in Cooper Companies were worth $32,680,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Byrne Asset Management LLC bought a new position in shares of Cooper Companies in the fourth quarter valued at approximately $33,000. OFI Invest Asset Management bought a new stake in shares of Cooper Companies in the 4th quarter worth $34,000. New Age Alpha Advisors LLC purchased a new stake in shares of Cooper Companies in the fourth quarter valued at about $38,000. Covestor Ltd boosted its holdings in Cooper Companies by 35.5% during the fourth quarter. Covestor Ltd now owns 458 shares of the medical device company’s stock worth $42,000 after purchasing an additional 120 shares during the last quarter. Finally, West Financial Advisors LLC bought a new stake in Cooper Companies in the 4th quarter worth about $49,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Cooper Companies Price Performance

Shares of NASDAQ COO opened at $79.51 on Friday. The firm has a market capitalization of $15.90 billion, a P/E ratio of 40.77, a P/E/G ratio of 2.25 and a beta of 1.01. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The stock’s 50-day simple moving average is $83.06 and its two-hundred day simple moving average is $93.67. The Cooper Companies, Inc. has a twelve month low of $69.81 and a twelve month high of $112.38.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The business had revenue of $964.70 million for the quarter, compared to the consensus estimate of $981.25 million. As a group, equities analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on COO. Robert W. Baird reduced their target price on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a report on Friday, March 7th. BNP Paribas upgraded Cooper Companies to a “hold” rating in a research note on Thursday, March 13th. JPMorgan Chase & Co. reduced their price target on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research report on Friday, March 7th. Finally, Stifel Nicolaus lowered their price target on shares of Cooper Companies from $115.00 to $105.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $110.25.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.